Novartis Financials - Benzinga

Novartis AG

NVSNYSE

Trade with Public

Trade with Public

$151.72

-0.60-0.39%

At close: Aug 13, 5:00 PM EST

$151.83

0.110.07%

After Hours: 4:03 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Dividends Compare Options Stock Report

Novartis Financials

Novartis (NVS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.

Vandana Singh

Earnings Scheduled For July 21, 2026

Companies Reporting Before The Bell • Mueller Industries (NYSE:MLI) is projected to report quarterly earnings at $1.15 per share on revenue of $1.27 billion. • Valmont Industries (NYSE:VMI) is projected to report

Benzinga Insights

PRO
Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2

Full-year 2026 guidance reaffirmed o Net sales expected to grow low single-digit and core operating income expected to decline low single-digit

Benzinga Newsdesk

PRO
Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate

Novartis (NYSE:NVS) reported quarterly earnings of $2.41 per share which beat the analyst consensus estimate of $2.13 by 13.15 percent. This is a 0.41 percent decrease over earnings of $2.42 per share from the same

Benzinga Newsdesk

Earnings Scheduled For April 28, 2026

Benzinga Insights

PRO
Novartis Reaffirms FY2026 Outlook; Net Sales to Grow Low Single-Digit, Core Operating Income to Decline Low Single-Digit

Full year 2026 guidance2 reaffirmed o Net sales expected to grow low single-digit and core operating income expected to decline low single-digit

Benzinga Newsdesk